• HLS Therapeutics management commentary attributed Q3 2026 revenue growth of 4.8% to Vascepa demand and NILEMDO sales.
• Adjusted EBITDA edged up to USD 4.95 million from USD 4.92 million, while NILEMDO launch investment increased operating expenses.
• Nine-month adjusted EBITDA fell 6% to USD 13.08 million, primarily reflecting higher spending on the NILEMDO launch.
• Lower interest expenses reflected a cheaper credit agreement and debt repayments, helping narrow the quarterly net loss to USD 2.23 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HLS Therapeutics Inc. published the original content used to generate this news brief on November 12, 2026, and is solely responsible for the information contained therein.